Imaradenant is under clinical development by Sosei Group and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Imaradenant’s likelihood of approval (LoA) and phase transition for Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer took place on 12 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Imaradenant Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Imaradenant overview

Imaradenant is under development for the treatment of solid tumors including colorectal cancer, non-small cell lung cancer, metastatic castration resistant prostate cancer and was under development for the treatment of Parkinson's disease, attention disorders including attention deficit hyperactivity disorder (ADHD). The drug candidate is a novel, small molecule which is administered orally. It is acts as adenosine A2A antagonist. It is based on structure-based drug discovery (SBDD) technology.

Sosei Group overview

Sosei Group (Sosei) is a biopharmaceutical company that develops and commercializes drugs. Its medical products include Ultibro, Seebri, Enerzair, Breezhaler, and Oravi. The company’s in-house pipeline programs include H4 antagonist, EP4 antagonist, SARS-CoV-2 MPro, GPR52 agonist, and PAR2 mAb. Sosei partnered pipeline program comprises Adenosine A2a antagonist, GLP-1 agonist, CCR6 antagonist, MC4 antagonist, CGRP antagonist, GPR35 agonist, CXCR4 mAb, PAR2 Peptide, targeted GPCR degradation, AI-augmented drug discovery, Ion Channels, mGlu5 NAM, and OX2 agonists. It develops medicines in the therapeutic areas of gastroenterology, neurology, immunology, and inflammatory diseases. The company operates in Japan, Ireland, and the UK. Sosei is headquartered in Chiyoda-ku, Tokyo, Japan.

Quick View Imaradenant LOA Data

Report Segments
  • Innovator
Drug Name
  • Imaradenant
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
  • Oncology
Key Developers
  • Sponsor Company: Sosei Group
  • Originator: Heptares Therapeutics
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.